Literature DB >> 31741863

The effect of intravenous high-dose glucocorticoids and orbital decompression surgery on sight-threatening thyroid-associated ophthalmopathy.

Yun Wen1, Jian-Hua Yan1.   

Abstract

AIM: To report the effects of intravenous high-dose glucocorticoids (ivGC) and orbital decompression (OD) surgery for treatment of sight-threatening thyroid-associated ophthalmopathy (TAO).
METHODS: A retrospective review of medical records from patients with sight-threatening TAO [definite or highly suspected dysthyroid optic neuropathy (DON)] treated with ivGC (60 cases) and OD (25 cases) was conducted at the Zhongshan Ophthalmic Center between January 2001 and January 2009. Patients were initially treated with ivGC (ivGC group). If no significant improvement in visual function was obtained, they then received OD surgery (OD group). The pre- versus post-treatment efficacies of either ivGC or OD in these patients were assessed using several indices, including visual acuity, intraocular pressure, ocular alignment, ocular motility, and exophthalmos.
RESULTS: Nighty-one eyes had definite DON while 79 were considered to have highly suspected DON. In the ivGC group, 51 individuals (85.0%) eventually demonstrated normal vision, while 10 patients (16.7%) demonstrated a reduction in deviation (P<0.01), and 35 cases (58.3%) showed slight improvements in ocular motility (P<0.01). In OD group, visual acuity improved in 24 cases (96.0%, P<0.01) and all patients showed varying reductions of exophthalmos (mean: 4.35±1.13 mm, P<0.01). Eight cases (32.0%) experienced an 8-15 PD reduction of deviation and ocular motility improved in 12 cases (48.0%), while 3 patients (12.0%) developed new-onset strabismus with diplopia post-surgically (P<0.01). Patients were followed up at an average of 1.55±1.07y.
CONCLUSION: Both ivGC and OD show good therapeutic efficacy in the treatment of sight-threatening TAO. The presence of extremely poor eyesight (≥0.5logMAR) was corrected in some patients with ivGC alone, thus sparing these patients from subsequent OD surgery. In patients who were refractory to steroids, subsequent OD surgery often provided satisfactory outcomes, however, new-onset strabismus with diplopia was observed in 12.0% of these cases. International Journal of Ophthalmology Press.

Entities:  

Keywords:  dysthyroid optic neuropathy; glucocorticoids; orbital decompression; orbital surgery; thyroid-associated ophthalmopathy

Year:  2019        PMID: 31741863      PMCID: PMC6848872          DOI: 10.18240/ijo.2019.11.12

Source DB:  PubMed          Journal:  Int J Ophthalmol        ISSN: 2222-3959            Impact factor:   1.779


  32 in total

Review 1.  Orbital decompression for thyroid eye disease.

Authors:  Daniel B Rootman
Journal:  Surv Ophthalmol       Date:  2017-03-24       Impact factor: 6.048

Review 2.  Graves' Disease.

Authors:  Terry J Smith; Laszlo Hegedüs
Journal:  N Engl J Med       Date:  2016-10-20       Impact factor: 91.245

3.  Surgical effects of various orbital decompression methods in thyroid-associated orbitopathy: computed tomography-based comparative analysis.

Authors:  Kyoung Woo Kim; Jun Soo Byun; Jeong Kyu Lee
Journal:  J Craniomaxillofac Surg       Date:  2014-03-31       Impact factor: 2.078

Review 4.  Thyroid eye disease: a review.

Authors:  Danielle L Weiler
Journal:  Clin Exp Optom       Date:  2016-10-04       Impact factor: 2.742

Review 5.  Clinical review: Intravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity.

Authors:  S Zang; K A Ponto; G J Kahaly
Journal:  J Clin Endocrinol Metab       Date:  2011-01-14       Impact factor: 5.958

6.  Clinical features of dysthyroid optic neuropathy: a European Group on Graves' Orbitopathy (EUGOGO) survey.

Authors:  David McKeag; Carol Lane; John H Lazarus; Lelio Baldeschi; Kostas Boboridis; A Jane Dickinson; A Iain Hullo; George Kahaly; Gerry Krassas; Claudio Marcocci; Michele Marinò; Maarten P Mourits; Marco Nardi; Christopher Neoh; Jacques Orgiazzi; Petros Perros; Aldo Pinchera; Susanne Pitz; Mark F Prummel; Maria S Sartini; Wilmar M Wiersinga
Journal:  Br J Ophthalmol       Date:  2006-10-11       Impact factor: 4.638

7.  Use of MRI signal intensity of extraocular muscles to evaluate methylprednisolone pulse therapy in thyroid-associated ophthalmopathy.

Authors:  Tomoaki Higashiyama; Yasuhiro Nishida; Katsutaro Morino; Satoshi Ugi; Yoshihiko Nishio; Hiroshi Maegawa; Masahito Ohji
Journal:  Jpn J Ophthalmol       Date:  2014-12-03       Impact factor: 2.447

8.  Strabismus after inferior-medial wall orbital decompression in thyroid-related orbitopathy.

Authors:  Ido D Fabian; Nachum Rosen; Guy J Ben Simon
Journal:  Curr Eye Res       Date:  2012-08-06       Impact factor: 2.424

9.  Results and predictability of fat-removal orbital decompression for disfiguring graves exophthalmos in an Asian patient population.

Authors:  Chien-Hsiu Wu; Tien-Chun Chang; Shu-Lang Liao
Journal:  Am J Ophthalmol       Date:  2008-02-01       Impact factor: 5.258

10.  Short and long-term effects of high-dose intravenous methylprednisolone pulse therapy on thyroid-associated ophthalmopathy.

Authors:  Xiaomei Liu; Shu Wang; Li Qin; Wei Qiang; Mahesh Dahal; Ping Fan; Shan Gao; Bingyin Shi
Journal:  Exp Ther Med       Date:  2016-06-09       Impact factor: 2.447

View more
  4 in total

Review 1.  Therapeutic difference between orbital decompression and glucocorticoids administration as the first-line treatment for dysthyroid optic neuropathy: a systematic review.

Authors:  Ming-Na Xu; Zhao-Qi Pan; Yun-Hai Tu; He-Qing Tao; Ke-Si Shi; Wen-Can Wu
Journal:  Int J Ophthalmol       Date:  2021-07-18       Impact factor: 1.779

2.  Management of patients with dysthyroid optic neuropathy treated with intravenous corticosteroids and/or orbital decompression surgery.

Authors:  Sandra Rezar-Dreindl; Andrea Papp; Arnulf Baumann; Thomas Neumayer; Katharina Eibenberger; Eva Stifter; Ursula Schmidt-Erfurth
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-06-22       Impact factor: 3.535

3.  The Therapeutic Effect of Combination of Orbital Decompression Surgery and Methylprednisolone Pulse Therapy on Patients with Bilateral Dysthyroid Optic Neuropathy.

Authors:  Jianan Xu; Huijing Ye; Guo Chen; Jingqiao Chen; Rongxin Chen; Huasheng Yang
Journal:  J Ophthalmol       Date:  2020-02-19       Impact factor: 1.909

4.  Early efficacy of teprotumumab for the treatment of dysthyroid optic neuropathy: A multicenter study.

Authors:  Connie M Sears; Yao Wang; Lucy A Bailey; Roger Turbin; Prem S Subramanian; Raymond Douglas; Kimberly Cockerham; Andrea L Kossler
Journal:  Am J Ophthalmol Case Rep       Date:  2021-05-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.